Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Idiopathic pulmonary fibrosis management

Lungs (Skypixel/Dreamstime)Summary

Idiopathic pulmonary fibrosis causes irreversible damage to the lungs, and pharmacological cure is not possible. Patients who are diagnosed with the disease have complex management needs and should be cared for by specialist multidisciplinary teams.

Treatment is aimed at slowing the progression of the disease, alleviating symptoms, preventing exacerbations and improving quality of life. Oxygen therapy and pulmonary rehabilitation are currently the main treatment options and an increasing number of pharmacological options aimed at slowing disease progression are becoming available.

Lloyd Mayers is a respiratory pharmacist at North Bristol NHS Trust and Patricia Ging is transplant and pulmonary hypertension pharmacist at Mater Misericordiae University Hospital in Dublin, Ireland.


Citation: Clinical Pharmacist DOI: 10.1211/CP.2013.11127259

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary information

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.